Outpatient Oncology Infusion Market by Treatment Type (Chemotherapy Infusion, Immunotherapy Infusion, Targeted Therapy Infusion, Hormone Therapy Infusion), by End User (Hospitals, Ambulatory Surgical Centers, Physician Offices, Homecare Services), by Mode of Administration (Intravenous IV, Subcutaneous SC, Intramuscular IM, Oral Therapy), by Infusion System Type (Manual Infusion Systems, Electronic Infusion Systems), by Service Type (Infusion Services, Nutritional Support Services, Pain Management Services), by Infusion Setting (Outpatient Clinics, Home Infusion Therapy); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Outpatient Oncology Infusion Market was valued at USD 15.3 Billion in 2024-e and will surpass USD 22.3 Billion by 2030; growing at a CAGR of 6.5% during 2025 - 2030.

The outpatient oncology infusion market is an essential segment of the healthcare industry, catering to cancer patients who require infusion therapies, such as chemotherapy, immunotherapy, targeted therapy, and hormone therapy, outside the traditional inpatient hospital setting. With advancements in treatment protocols and growing patient preference for receiving care in more comfortable and convenient settings, outpatient oncology infusion is becoming increasingly popular. This market is further bolstered by improvements in infusion technology, homecare services, and a shift towards value-based care models, enabling patients to receive high-quality treatments while reducing hospital stays and healthcare costs.

The growing incidence of cancer globally, coupled with the development of new and effective infusion therapies, is driving the market. Patients and healthcare providers are increasingly opting for outpatient settings such as ambulatory surgical centers and homecare services, where therapies can be administered with greater flexibility and convenience. This shift is also supported by advancements in infusion systems, such as electronic infusion devices that enhance precision and safety, leading to a positive outlook for the market.

Chemotherapy Infusion Is the Largest Treatment Type

Chemotherapy infusion remains the largest treatment type in the outpatient oncology infusion market. Chemotherapy, a cornerstone of cancer treatment, continues to be widely used for various types of cancer, such as breast, lung, and colorectal cancer. The growing prevalence of cancer and the need for effective treatment options are driving the demand for chemotherapy infusion in outpatient settings.

Advancements in chemotherapy protocols and the development of new chemotherapeutic agents that can be more effectively administered in outpatient settings have contributed to the growing demand for outpatient chemotherapy infusions. Furthermore, the convenience of receiving treatment on an outpatient basis, along with improved patient management, is contributing to the increasing preference for outpatient chemotherapy. As cancer treatment protocols evolve, chemotherapy infusion will continue to dominate the outpatient oncology infusion market.

Homecare Services Is the Fastest-Growing End-User

Homecare services represent the fastest-growing end-user segment in the outpatient oncology infusion market. As patients seek more comfortable and cost-effective treatment options, homecare services have emerged as a viable alternative to traditional hospital-based care. Infusion therapies, including chemotherapy and immunotherapy, are increasingly being administered at home, providing patients with convenience and the ability to remain in familiar surroundings while receiving treatment.

The rise of homecare services is driven by technological advancements, such as portable infusion pumps and remote monitoring systems, which allow healthcare professionals to monitor patients’ progress without the need for hospitalization. The growing patient preference for home-based care, combined with the availability of specialized infusion services at home, is expected to accelerate the adoption of homecare services, making it the fastest-growing segment within the market.

Intravenous (IV) Administration Dominates the Mode of Administration

Intravenous (IV) administration is the dominant mode of administration in the outpatient oncology infusion market. IV infusion is the most common and effective method for delivering chemotherapy, immunotherapy, and other oncological treatments, ensuring rapid delivery of medications directly into the bloodstream. The ability to precisely control the dosage and infusion rate, coupled with the safety and efficacy of IV infusion, makes it the preferred choice for oncology treatments.

The convenience of administering IV infusions in outpatient settings, such as clinics, ambulatory centers, and homecare services, further enhances its popularity. As a result, the demand for intravenous administration is expected to continue to grow, solidifying its position as the leading mode of administration in the outpatient oncology infusion market.

Electronic Infusion Systems Are Leading the Infusion System Type

Electronic infusion systems lead the infusion system type segment in the outpatient oncology infusion market. These systems offer several advantages over manual infusion systems, including improved precision, reduced human error, and better monitoring of infusion rates. Electronic infusion pumps are also equipped with features such as alarms, safety checks, and automated drug libraries that reduce the risk of adverse events, making them a preferred choice for the safe administration of chemotherapy, immunotherapy, and other oncology treatments.

The adoption of electronic infusion systems is further supported by their integration with digital healthcare solutions, enabling better tracking of patient treatment regimens, optimizing infusion protocols, and ensuring efficient healthcare delivery. As the demand for enhanced safety and precision in cancer treatments rises, the preference for electronic infusion systems will continue to drive market growth in this segment.

Outpatient Clinics Are the Largest Infusion Setting

Outpatient clinics dominate the infusion setting segment within the outpatient oncology infusion market. These clinics provide a convenient, accessible, and cost-effective alternative to inpatient hospital settings for cancer patients receiving infusion therapies. Outpatient clinics are well-equipped with advanced infusion technologies and skilled medical staff to manage patients undergoing chemotherapy, immunotherapy, and other oncology treatments.

The increasing focus on reducing healthcare costs, along with the growing adoption of outpatient care models, is fueling the preference for outpatient clinics. Additionally, outpatient clinics allow for greater patient comfort and a more personalized approach to cancer treatment, further boosting their popularity. As outpatient care continues to evolve, outpatient clinics will remain the largest segment in the outpatient oncology infusion market.

North America Holds the Largest Market Share

North America holds the largest market share in the outpatient oncology infusion market, primarily driven by the high prevalence of cancer and advanced healthcare infrastructure in the region. The United States, in particular, is a key contributor to the growth of the market, with a large number of outpatient clinics, ambulatory surgical centers, and homecare services that offer infusion therapies. The presence of leading healthcare providers and the availability of cutting-edge infusion technologies further support the growth of the market in North America.

The growing patient preference for outpatient care, coupled with the shift towards homecare services and the high adoption rate of electronic infusion systems, is expected to maintain North America's dominant position in the outpatient oncology infusion market. Furthermore, the increasing availability of insurance coverage for outpatient services and the rising focus on patient-centered care are likely to further drive market growth in the region.

Competitive Landscape

The outpatient oncology infusion market is highly competitive, with key players including Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, ICU Medical, Inc., and Smiths Medical. These companies are focusing on expanding their product offerings, enhancing the safety and efficiency of infusion therapies, and investing in technological innovations such as electronic infusion pumps and homecare infusion solutions.

The competitive landscape is characterized by strategic partnerships, collaborations, and acquisitions aimed at strengthening product portfolios and expanding market reach. Companies are also focusing on improving customer service and offering comprehensive infusion services, such as pain management and nutritional support, to meet the growing demands of cancer patients. With the ongoing advancements in infusion technology and the increasing preference for outpatient care, the market will continue to see significant competition and innovation.

Recent Developments:

• McKesson Corporation expanded its infusion services offering with a new digital platform for at-home oncology treatments in January 2025.
• Cardinal Health launched an innovative targeted therapy infusion system aimed at improving patient experience in outpatient clinics in December 2024.
• AmerisourceBergen partnered with a leading homecare service provider to enhance home infusion oncology services in November 2024.
• CVS Health introduced a new line of oncology support services to complement outpatient infusion therapy in October 2024.
• Fresenius Medical Care upgraded its outpatient oncology infusion services with cutting-edge, patient-focused care solutions in September 2024.

List of Leading Companies:

• McKesson Corporation
• Cardinal Health
• AmerisourceBergen
• Optum Health
• UPMC Pinnacle
• UnitedHealth Group
• Express Scripts
• Cigna
• Walgreens Boots Alliance
• CVS Health
• Fresenius Medical Care
• Baxter International Inc.
• Eisai Inc.
• Roche Holding AG
• Eli Lilly and Co.

Report Scope: